Hyderabad-based drugmaker NATCO Pharma has strengthened its presence in the United States by launching a generic version of a high-value oncology medication, marking a strategic milestone in its global expansion. The product introduction positions the company to capitalize on patent expirations in the U.S. pharmaceutical market while broadening access to cost-effective cancer treatments. The launch is expected to contribute meaningfully to revenue growth, given the significant annual sales of the branded reference drug.